Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Analyst consensus: Ten analysts give Inventiva an average "Buy" recommendation (1 sell, 6 buy, 3 strong buy) with a mean 1‑year price target of $16.56.
• Stock and fundamentals: IVA traded around $4.99 (50/200‑day MAs $5.83/$5.33, 52‑week range $2.85–$7.98) while recent quarterly EPS was −$0.16 on $0.01M revenue and analysts forecast −$1.17 EPS for the fiscal year.
• Clinical catalyst: The company’s lead drug, lanifibranor (IVA337), is in Phase III for NASH, which is the primary driver of analyst interest despite weak near‑term financials.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $16.5556.

A number of analysts recently issued reports on IVA shares. Truist Financial started coverage on Inventiva in a report on Thursday, March 19th. They issued a "buy" rating and a $13.00 price target for the company. Barclays began coverage on Inventiva in a report on Tuesday, January 27th. They issued an "overweight" rating and a $18.00 price target for the company. Leerink Partners began coverage on Inventiva in a report on Monday, January 12th. They set an "outperform" rating and a $12.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a report on Tuesday, April 21st. Finally, UBS Group began coverage on Inventiva in a report on Wednesday, January 7th. They set a "buy" rating and a $12.00 target price for the company.

Inventiva Trading Up 0.3%

Shares of NASDAQ IVA opened at $4.99 on Monday. The stock has a 50 day moving average price of $5.83 and a 200 day moving average price of $5.33. Inventiva has a 52-week low of $2.85 and a 52-week high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. Research analysts predict that Inventiva will post -1.17 earnings per share for the current fiscal year.

Institutional Trading of Inventiva

A number of hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC lifted its holdings in Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company's stock worth $142,000 after buying an additional 9,212 shares during the period. Creative Planning purchased a new stake in Inventiva during the second quarter worth $32,000. Commonwealth Equity Services LLC lifted its holdings in Inventiva by 19.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company's stock worth $361,000 after buying an additional 12,704 shares during the period. Virtu Financial LLC purchased a new stake in Inventiva during the fourth quarter worth $60,000. Finally, XTX Topco Ltd purchased a new stake in Inventiva during the fourth quarter worth $84,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.